{"groups":[{"description":"Open-label eltrombopag was supplied in 25, 50, 75 mg tablets. All subjects started at 50mg once daily and dose was increased or decreased based on platelet count (target range 50-200Gi/L). Alternate days and interruption of dosing was permitted to maintain target range of platelet count. Doses could range from 25 to 75mg. Subjects could remain on treatment up to 2 years.","id":"FG000","title":"Eltrombopag"}],"periods":[{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"42"}],"type":"Adverse Event"},{"reasons":[{"groupId":"FG000","numSubjects":"39"}],"type":"Withdrawal by Subject"},{"reasons":[{"groupId":"FG000","numSubjects":"39"}],"type":"Various -follow up w clinical team"},{"reasons":[{"groupId":"FG000","numSubjects":"32"}],"type":"Lack of Efficacy"},{"reasons":[{"groupId":"FG000","numSubjects":"8"}],"type":"Non-compliance"},{"reasons":[{"groupId":"FG000","numSubjects":"4"}],"type":"Lost to Follow-up"},{"reasons":[{"groupId":"FG000","numSubjects":"3"}],"type":"Protocol Violation"}],"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"302"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"51"}],"type":"Subjects From TRA100773A"},{"achievements":[{"groupId":"FG000","numSubjects":"61"}],"type":"Subjects From TRA100773B"},{"achievements":[{"groupId":"FG000","numSubjects":"146"}],"type":"Subjects From TRA102537 Raise"},{"achievements":[{"groupId":"FG000","numSubjects":"43"}],"type":"Subjects From TRA108057 Repeat"},{"achievements":[{"comment":"Mistakenly enrolled (not in any of the 3 trials) On 50 mg/d eltrombopag for 18 days and withdrawn","groupId":"FG000","numSubjects":"1"}],"type":"Unknown - Not From Previous Trial"},{"achievements":[{"groupId":"FG000","numSubjects":"135"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"167"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}],"recruitmentDetails":"Subjects were previously enrolled in a study of eltrombopag: TRA100773A, TRA100773B, TRA102537/RAISE, or TRA108057/REPEAT. Eligibility of consenting subjects was assessed during the screening period of up to 28 days prior to Day 1 of treatment."}